Working… Menu

Regorafenib and Nivolumab Simultaneous Combination Therapy (REGONIVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03406871
Recruitment Status : Completed
First Posted : January 23, 2018
Last Update Posted : April 26, 2021
Ono Pharmaceutical Co. Ltd
Bayer Yakuhin, Ltd.
Information provided by (Responsible Party):
Kohei Shitara, National Cancer Center Hospital East